HIL-214
Prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection
Key Facts
About HilleVax
HilleVax is a Boston-based biotech company dedicated to preventing life-threatening diseases through innovative vaccine development. Its primary asset, HIL-214, is a bivalent VLP vaccine targeting norovirus, a leading cause of severe acute gastroenteritis worldwide with no approved vaccines. The company was founded by experienced Takeda Vaccines executives and went public in 2022, positioning itself to advance its late-stage clinical program and build a pipeline of additional vaccine candidates.
View full company profileAbout HilleVax
HilleVax is a Boston-based biotech company dedicated to preventing life-threatening diseases through innovative vaccine development. Its primary asset, HIL-214, is a bivalent VLP vaccine targeting norovirus, a leading cause of severe acute gastroenteritis worldwide with no approved vaccines. The company was founded by experienced Takeda Vaccines executives and went public in 2022, positioning itself to advance its late-stage clinical program and build a pipeline of additional vaccine candidates.
View full company profile